{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218198","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2026-05-12T11:39:12+00:00","discovered_at":"2026-05-12T11:40:00.383958+00:00","generated_at":"2026-05-12T11:40:17.205252+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coya Therapeutics Q1 net loss $7.2M; cash $50.7M; FDA Fast Track for COYA 302 in ALS","bullets":["Net loss $7.2M vs $7.3M YoY; R&D expense fell to $4.1M (down $1.1M), G&A rose to $3.4M (up $1.1M).","Cash and cash equivalents $50.7M as of March 31, 2026.","FDA granted Fast Track Designation to COYA 302 for ALS on March 11, 2026.","ALSTARS Phase 2 trial now in full recruitment; topline readout expected Q1 2027.","Completed $11.1M private placement led by Dr. Reddy's ($10M) and Greenlight Capital ($1.1M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218198","json":"https://secwatch.observer/filing/0001193125-26-218198.json","markdown":"https://secwatch.observer/filing/0001193125-26-218198.md","text":"https://secwatch.observer/filing/0001193125-26-218198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526218198/0001193125-26-218198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526218198/coya-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:40:17.205252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}